Last updated: February 13, 2026
What is the Drug?
NDC 70677-1064 refers to Hepatitis C Virus (HCV) treatment, likely a fixed-dose combination product from Gilead Sciences, such as Epclusa (sofosbuvir and velpatasvir). Gilead's Epclusa gained FDA approval in June 2016 for treating all genotypes (1-6) of chronic hepatitis C.
Market Size and Demand Drivers
Global Hepatitis C Market:
The HCV treatment market has grown substantially, driven by rising prevalence and improved therapy options.
- Prevalence: Approximately 58 million people have chronic HCV globally (WHO, 2022).
- Market Growth: The U.S. alone features around 2.4 million infected individuals, with an annual treatment cohort of roughly 100,000 cases (IQVIA, 2021).
Key Factors Influencing Demand:
- Increased screening for HCV.
- Expanded treatment guidelines including all genotypes.
- High cure rates (>95%) of direct-acting antivirals (DAAs).
- Price reductions via competition and generic entry in some regions.
Competitive Landscape
Primary competitors of NDC 70677-1064 include:
- Harvoni (ledipasvir/sofosbuvir), Gilead.
- Mavyret (glecaprevir/pibrentasvir), AbbVie.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Gilead.
Market trends include:
- Increasing generic competition outside the U.S.
- Consolidation among pharmaceutical firms.
- Shift towards simplified, pan-genotypic regimens.
Price Trends and Projections
Current Pricing:
- U.S. list price: Approx. $24,000 per 12-week course (Gilead, 2021).
- Negotiated prices: Vary by payers; average net price closer to $25,000-$30,000 per treatment course.
- Global variation: Prices are substantially lower in Europe, Asia, and emerging markets due to price controls and generic penetration.
Historical Changes:
- Since approval, the initial list prices for Gilead’s regimens exceeded $80,000 per treatment course.
- Price reductions of over 70% have occurred due to market competition and patent challenges.
Projection Assumptions (Next 3–5 years):
- Continued patent protections for Gilead’s key products until 2030s, barring patent challenges.
- Emerging generics and biosimilars could reduce prices by 50-70% in mature markets.
- Increased use of pan-genotypic regimens driving volume but flattening average per-unit revenue.
- Price sensitivity in institutional and government payers will sustain discounts.
| Projected Price Range (2024–2028): |
Region |
Price Range per 12-week course |
Key Factors |
| U.S. |
$15,000 – $25,000 |
Patent protections, payer discounts, market volume |
| Europe |
$10,000 – $15,000 |
Price negotiations, government tenders |
| Emerging markets |
$1,000 – $5,000 |
Generic competition, price controls |
Note: Exact price projections depend on patent status, regulatory changes, and market entry of generics.
Market Opportunities and Risks
Opportunities:
- Growing screening and diagnosis rates.
- Increasing treatment coverage in low- and middle-income countries (L/MIC).
- Development of combination products and extended indications.
Risks:
- Patent litigation or patent expiries could accelerate generic entry.
- Price-sensitive markets may limit revenue potential.
- Competition from newer regimens with shorter durations or fewer side effects.
Key Takeaways
- NDC 70677-1064 likely represents Gilead’s pan-genotypic hepatitis C treatment.
- The global hepatitis C market exhibits steady growth, driven by increasing diagnosis and treatment.
- Prices in the U.S. remain high but are declining due to market competition; in other regions, prices are dropping faster because of generics and negotiations.
- Over the next five years, prices are expected to decline further, especially where patent challenges succeed or generics enter markets heavily.
- Market volume will grow primarily through enhanced screening and expanded treatment guidelines, but revenue growth may plateau once major patents expire or treatment saturation occurs.
FAQs
1. How will patent expiries affect prices of NDC 70677-1064?
Patent expiries typically enable generic competitors to enter markets, resulting in significant price reductions—potentially 50-70%.
2. What licensing or regulatory changes could impact market size?
Easier access through simplified approval pathways or expanded indications could increase market size; restrictive licensing or patent disputes could limit growth.
3. How does the presence of generics influence price projections?
Generics usually reduce average treatment costs, especially outside the U.S., where patent protections are weaker.
4. Are new hepatitis C treatments likely to replace NDC 70677-1064?
Emerging therapies with shorter durations or improved safety profiles could displace existing regimens in some markets within 3-5 years.
5. What geographical differences impact pricing strategies?
Pricing negotiations, license laws, and market access policies vary widely; high-income countries tend to pay more, with lower prices in developing regions driven by generics.
Sources
[1] WHO Global Hepatitis Report 2022
[2] IQVIA, Market Estimates and Trends Report 2021
[3] Gilead Sciences, Annual Product Price Reports 2021
